# Hodgkin lymphoma

Source: https://onco.cc/cancers/hodgkin-lymphoma/  
OnCo record `hodgkin-lymphoma` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab.

## Summary

Classical Hodgkin lymphoma is a B-cell cancer in which rare, giant Reed-Sternberg cells (about 1% of the mass) recruit an inflammatory microenvironment and hide behind amplified PD-L1. It peaks in young adults and again after 55, is staged with PET-CT and the Lugano system, and is cured in more than 85% of patients overall and in over 90% of early-stage disease. Because most patients are young and will live for decades, the field's defining problem is not cure but the cost of cure: anthracycline heart disease, bleomycin lung injury, infertility, and second cancers from alkylators and radiation.

That is why Hodgkin lymphoma pioneered response-adapted therapy. Interim PET after two cycles (Deauville score) steers de-escalation (drop bleomycin after negative PET2 in RATHL; omit radiotherapy in early stage in HD16/HD17/RAPID at a small PFS cost) or escalation to BEACOPP-type regimens. Two ADC- and immunotherapy-based regimens then replaced ABVD for advanced disease: brentuximab vedotin-AVD (ECHELON-1, overall survival benefit) and, from March 2026, nivolumab-AVD (SWOG S1826, PFS HR 0.45 versus BV-AVD, neuropathy halved, children and adults together). In Europe, GHSG HD21's PET-guided BrECADD matches escalated BEACOPP's ~94% PFS with far less toxicity. Relapse is treated with PD-1 blockade (pembrolizumab beat brentuximab in KEYNOTE-204), brentuximab, salvage chemotherapy and autologous transplant, with brentuximab consolidation for high-risk patients (AETHERA); allogeneic transplant and CD30 CAR-T are options for the few who fail everything.

The next questions are how far chemotherapy can be removed. AHOD2131 tests brentuximab-nivolumab in early-stage disease across children and adults; ctDNA may replace PET for steering; older patients, who have half the cure rate of young ones, need regimens they can tolerate (nivolumab-AVD, brentuximab-based). Survivorship care for the tens of thousands cured decades ago, and the shift from radiotherapy to systemic de-escalation, remain the field's distinctive concerns.

## Fields

- Kind: Cancer
- Last checked: 2026-09-07
- Tags: heme; spike
- Group: haematologic
- Burden: ~83,000 new cases a year worldwide, ~8,500 in the US, with age peaks at 20-30 and over 55. More than 85% are cured, so the research agenda is curing with less toxicity. Five-year survival is ~89% overall in high-income countries; ~23,000 deaths a year worldwide.
- Subtypes: Classical Hodgkin lymphoma: nodular sclerosis (most common in young adults), mixed cellularity, lymphocyte-rich, lymphocyte-depleted; Nodular lymphocyte-predominant B-cell lymphoma (reclassified 2022; indolent, CD20+, rituximab-responsive); Early stage (I-II) favourable vs unfavourable (bulk, ESR, ≥3 sites); Advanced stage (III-IV); IPS 0-7 risk score; Paediatric / adolescent-young-adult vs older (>60) disease; EBV-positive (more common in children, older adults, and low-income settings)
- Biomarkers: Interim PET (Deauville); CD30; PD-L1 (9p24.1 amplification); Interim PET (Deauville score) after cycle 2; CD30 and CD15 on Reed-Sternberg cells; CD20 in NLPBL; 9p24.1 (PD-L1/PD-L2) amplification; EBV status (EBER); International Prognostic Score (IPS); Baseline metabolic tumour volume; ctDNA (research; PhasED-seq); Soluble CD30 (research)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/hodgkin-lymphoma/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/hodgkin-lymphoma/#overview [4 subtypes, 7 state-of-the-art points]
- What it is (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/hodgkin-lymphoma/#what-it-is [10 subtypes]
- Finding it (on the hub): How it shows itself, how it is confirmed, what screening exists, and the biomarkers clinicians test for. https://onco.cc/cancers/hodgkin-lymphoma/#finding-it [11 biomarkers, 3 prevalence rows]
- Treating it (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/hodgkin-lymphoma/#treating-it [9 settings, 11 regimens, 9 decisions with options]
- Evidence (own page): Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/hodgkin-lymphoma/evidence/ [55 trials, 4 key papers, 19 milestones]
- The science (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/hodgkin-lymphoma/#science [29 targets, 1 pathway]
- Where you are (own page): Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record. https://onco.cc/cancers/hodgkin-lymphoma/where-you-are/ [12 centres]
- Living with it (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/hodgkin-lymphoma/#living-with-it [32 questions, 6 red cards]
- What is coming (own page): Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/hodgkin-lymphoma/coming/ [32 medicines, 55 trials, 14 ideas, 9 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/hodgkin-lymphoma/data/ [241 connected records]

## Standard of care

- Advanced stage: Nivolumab-AVD (2026) or BV-AVD; PET-adapted. ([Nivolumab](https://onco.cc/drugs/nivolumab/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [FDG PET](https://onco.cc/technologies/fdg-pet/))
- Early stage, favourable (I-II): ABVD × 2 + involved-site radiotherapy 20 Gy (HD10), or PET-adapted omission of radiotherapy after 3 cycles if PET-negative (RAPID, HD16) accepting ~5% lower PFS; AHOD2131 tests BV-nivo. ([Doxorubicin](https://onco.cc/drugs/doxorubicin/), [PET-adapted (response-adapted) therapy](https://onco.cc/technologies/pet-adapted-therapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Deauville five-point scale](https://onco.cc/terms/deauville-score/), [AHOD2131 (COG / NCTN)](https://onco.cc/trials/ahod2131/))
- Early stage, unfavourable (I-II bulky or risk factors): ABVD × 4 + ISRT 30 Gy, or escalated BEACOPP × 2 + ABVD × 2 + RT (HD14/HD17 PET-guided); nivolumab- or BV-containing regimens in trials. ([Doxorubicin](https://onco.cc/drugs/doxorubicin/), [PET-adapted (response-adapted) therapy](https://onco.cc/technologies/pet-adapted-therapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/))
- Advanced stage (III-IV), age ≤60: Nivolumab-AVD × 6 (S1826; approved March 2026, no routine radiotherapy) or BV-AVD × 6 with G-CSF (ECHELON-1); in Europe PET-guided BrECADD × 4-6 (HD21) or eBEACOPP; PET-adapted ABVD/AVD (RATHL) where novel agents unavailable. ([SWOG S1826](https://onco.cc/trials/swog-s1826/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [ECHELON-1](https://onco.cc/trials/echelon-1/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [GHSG HD21](https://onco.cc/trials/hd21/), [RATHL](https://onco.cc/trials/rathl/), [PD-1 blockade + AVD chemotherapy](https://onco.cc/pairings/pd1-plus-avd-hodgkin/))
- Advanced stage, age >60: Nivolumab-AVD (S1826 included older adults with less toxicity than BV-AVD); sequential brentuximab → AVD → brentuximab; avoid bleomycin; ABVD/AVD with dose adaptation. ([SWOG S1826](https://onco.cc/trials/swog-s1826/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF](https://onco.cc/pairings/bleomycin-omission-caution/))
- First relapse, transplant-eligible: Salvage (ICE, DHAP, GVD, BV-nivolumab or pembrolizumab-GVD) → PET-negative → high-dose therapy and autologous transplant; brentuximab consolidation for high-risk (AETHERA); PD-1 maintenance in trials. ([Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [AETHERA](https://onco.cc/trials/aethera/))
- Relapse after transplant or transplant-ineligible: Pembrolizumab (KEYNOTE-204) or nivolumab; brentuximab vedotin if not yet given; BV + nivolumab; allogeneic transplant for fit patients after response; CD30 CAR-T in trials; palliative radiotherapy or bendamustine. ([Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [KEYNOTE-204](https://onco.cc/trials/keynote-204/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [CheckMate 205](https://onco.cc/trials/checkmate-205/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [CD30 CAR-T for multiply relapsed Hodgkin lymphoma](https://onco.cc/ideas/idea-cd30-car-t-hodgkin/))
- Paediatric (COG / EuroNet): Risk-adapted OEPA/COPDAC (EuroNet-PHL-C2) or ABVE-PC with brentuximab (AHOD1331, EFS benefit) and PET-guided radiotherapy omission; S1826 and AHOD2131 now enrol from age 12 or 5. ([Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [PET-adapted (response-adapted) therapy](https://onco.cc/technologies/pet-adapted-therapy/), [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/), [AHOD1331](https://onco.cc/trials/ahod1331/), [EuroNet-PHL-C2](https://onco.cc/trials/euronet-phl-c2/))
- Survivorship: Lifelong surveillance for cardiac disease (anthracycline, mediastinal RT), breast cancer screening from 8 years after chest RT in women, thyroid and lung checks, fertility counselling before therapy. ([Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/))

## State of the art

- Immunotherapy in first line with less toxicity.
- Nivolumab-AVD is the new frontline standard for advanced disease (S1826: 2-year PFS 92%, neuropathy halved), approved March 2026 for ages 12 and up.
- Two intensive but de-toxified European options: PET-guided BrECADD (HD21) achieves ~94% 5-year PFS with 40% less morbidity than eBEACOPP.
- Interim PET steers therapy for nearly every patient: bleomycin omission (RATHL), radiotherapy omission (HD16/17, RAPID), cycle number (HD18, HD21).
- Radiotherapy is disappearing from advanced-stage care (<1% in S1826) and being minimised in early stage.
- PD-1 blockade is the most effective single agent in any lymphoma relapse (ORR ~70%), and beat brentuximab head to head (KEYNOTE-204).
- Cure rates above 90% in young patients shift the research agenda to late effects and to older adults.

## Open problems

- Late toxicity in survivors.
- Older patients.
- Late effects dominate: cardiac disease, breast and lung cancer after mediastinal radiotherapy, infertility; survivors need lifelong surveillance that most health systems do not organise.
- Older patients (>60) have roughly half the cure rate and double the toxicity; the best regimen for them is unsettled.
- The ~10-15% with primary refractory or early-relapsing disease still need transplant; those failing PD-1 blockade have few options beyond allogeneic transplant.
- Interim PET has limited positive predictive value; ctDNA-guided designs are unproven.
- Access: brentuximab and nivolumab are costly and unavailable in many countries where EBV-positive Hodgkin lymphoma is common in children.
- Nodular lymphocyte-predominant disease is now a separate entity with little trial evidence of its own.
- Radiotherapy omission trades a few percent of PFS for lower late toxicity; the right trade-off differs by age and sex.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hodgkin_lymphoma
- Wikipedia: https://en.wikipedia.org/wiki/Hodgkin_lymphoma

## Connected records

- pairings: [Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF](https://onco.cc/pairings/bleomycin-omission-caution/), [Caution: cumulative anthracycline dose and the heart](https://onco.cc/pairings/doxorubicin-cardio-caution/), [PD-1 blockade + AVD chemotherapy](https://onco.cc/pairings/pd1-plus-avd-hodgkin/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)](https://onco.cc/technologies/ctdna-lymphoma-monitoring/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [FDG PET](https://onco.cc/technologies/fdg-pet/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Log-kill hypothesis (Skipper)](https://onco.cc/technologies/log-kill-hypothesis/), [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [PET-adapted (response-adapted) therapy](https://onco.cc/technologies/pet-adapted-therapy/), [Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)](https://onco.cc/technologies/quantitative-imaging-biomarkers/), [Strain echocardiography (global longitudinal strain)](https://onco.cc/technologies/strain-echocardiography-gls/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/)
- targets: [CD25 (IL-2 receptor alpha)](https://onco.cc/targets/cd25/), [CD30](https://onco.cc/targets/cd30/), [GATA3](https://onco.cc/targets/gata3/), [Glucocorticoid receptor (NR3C1)](https://onco.cc/targets/glucocorticoid-receptor/), [KLHDC8B](https://onco.cc/targets/klhdc8b/), [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/), [TUBA1A](https://onco.cc/targets/tuba1a/), [TUBA1B](https://onco.cc/targets/tuba1b/), [TUBA1C](https://onco.cc/targets/tuba1c/), [TUBA3C](https://onco.cc/targets/tuba3c/), [TUBA3E](https://onco.cc/targets/tuba3e/), [TUBA4A](https://onco.cc/targets/tuba4a/), [TUBB1](https://onco.cc/targets/tubb1/), [TUBB2A](https://onco.cc/targets/tubb2a/), [TUBB2B](https://onco.cc/targets/tubb2b/), [TUBB3](https://onco.cc/targets/tubb3/), [TUBB4A](https://onco.cc/targets/tubb4a/), [TUBB4B](https://onco.cc/targets/tubb4b/), [TUBB6](https://onco.cc/targets/tubb6/), [TUBB8](https://onco.cc/targets/tubb8/)
- drugs: [Abexinostat](https://onco.cc/drugs/abexinostat/), [AT101](https://onco.cc/drugs/at101/), [AZD3470](https://onco.cc/drugs/azd3470/), [AZD4512](https://onco.cc/drugs/azd4512/), [Bleomycin](https://onco.cc/drugs/bleomycin/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Carmustine](https://onco.cc/drugs/carmustine/), [CD19 t-haNK](https://onco.cc/drugs/cd19-t-hank/), [Chlorambucil](https://onco.cc/drugs/chlorambucil/), [Cobolimab](https://onco.cc/drugs/cobolimab/), [CTX112](https://onco.cc/drugs/ctx112/), [Dacarbazine](https://onco.cc/drugs/dacarbazine/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Englumafusp alfa](https://onco.cc/drugs/englumafusp-alfa/), [Favezelimab](https://onco.cc/drugs/favezelimab/), [JNJ-90014496](https://onco.cc/drugs/jnj-90014496/), [KRT-232](https://onco.cc/drugs/krt-232/), [Mechlorethamine (chlormethine)](https://onco.cc/drugs/mechlorethamine/), [MEN1703](https://onco.cc/drugs/men1703/), [MK-1045](https://onco.cc/drugs/mk-1045/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Palifermin](https://onco.cc/drugs/palifermin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Penpulimab](https://onco.cc/drugs/penpulimab/), [Prednisone](https://onco.cc/drugs/prednisone/), [Procarbazine](https://onco.cc/drugs/procarbazine/), [Rondecabtagene autoleucel](https://onco.cc/drugs/rondecabtagene-autoleucel/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Vinblastine](https://onco.cc/drugs/vinblastine/), [Vincristine](https://onco.cc/drugs/vincristine/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Cellectis](https://onco.cc/companies/cellectis/), [Children's Oncology Group (COG)](https://onco.cc/companies/childrens-oncology-group/), [Compass Therapeutics](https://onco.cc/companies/compass-therapeutics/), [Evopoint Biosciences](https://onco.cc/companies/evopoint-biosciences/), [Foresight Diagnostics](https://onco.cc/companies/foresight-diagnostics/), [German Breast Group (GBG)](https://onco.cc/companies/gbg/), [German Hodgkin Study Group](https://onco.cc/companies/ghsg/), [Haihe Biopharma](https://onco.cc/companies/haihe-biopharma/), [HOVON](https://onco.cc/companies/hovon/), [Kartos Therapeutics](https://onco.cc/companies/kartos-therapeutics/), [Leadiant Biosciences](https://onco.cc/companies/leadiant/), [LYSA (The Lymphoma Study Association)](https://onco.cc/companies/lysa/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/), [Nordic Lymphoma Group](https://onco.cc/companies/nordic-lymphoma-group/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/), [Ryvu Therapeutics](https://onco.cc/companies/ryvu-therapeutics/), [Shenzhen TargetRx](https://onco.cc/companies/shenzhen-targetrx/), [SWOG Cancer Research Network](https://onco.cc/companies/swog/), [Takeda](https://onco.cc/companies/takeda/)
- institutions: [American Society of Hematology](https://onco.cc/institutions/ash/), [BC Cancer](https://onco.cc/institutions/bc-cancer/), [Butaro Cancer Center of Excellence](https://onco.cc/institutions/butaro-cancer-center/), [Cancer Research UK](https://onco.cc/institutions/cruk/), [Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine](https://onco.cc/institutions/baylor-duncan/), [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [European Hematology Association](https://onco.cc/institutions/eha/), [IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola](https://onco.cc/institutions/sant-orsola-bologna/), [Juravinski Cancer Centre / Escarpment Cancer Research Institute](https://onco.cc/institutions/juravinski/), [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/), [University Hospital Southampton / Centre for Cancer Immunology](https://onco.cc/institutions/southampton-cancer/), [University Hospitals Birmingham / University of Birmingham Cancer Research Centre](https://onco.cc/institutions/birmingham-cancer-centre/)
- terms: [ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)](https://onco.cc/terms/abvd-beacopp/), [Adolescent and young adult (AYA) oncology](https://onco.cc/terms/aya-oncology/), [Autologous stem cell transplant (ASCT)](https://onco.cc/terms/autologous-transplant/), [Cancer during pregnancy](https://onco.cc/terms/cancer-in-pregnancy/), [Deauville five-point scale](https://onco.cc/terms/deauville-score/), [Deauville score and PET-adapted therapy](https://onco.cc/terms/deauville/), [Deep inspiration breath-hold (DIBH)](https://onco.cc/terms/deep-inspiration-breath-hold/), [Epstein-Barr virus (EBV) in cancer](https://onco.cc/terms/ebv-term/), [Lugano classification / Ann Arbor staging](https://onco.cc/terms/lugano-classification/), [Lymphoma (tissue type)](https://onco.cc/terms/lymphoma-type/), [Overall survival (OS)](https://onco.cc/terms/os/), [Progression-free survival (PFS)](https://onco.cc/terms/pfs/), [Reed-Sternberg cell](https://onco.cc/terms/reed-sternberg-cell/), [Second cancers after radiotherapy](https://onco.cc/terms/second-cancers-after-radiotherapy/)
- trials: [A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients](https://onco.cc/trials/nct04024696/), [A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies](https://onco.cc/trials/nct05006716/), [A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies](https://onco.cc/trials/nct05589896/), [A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom](https://onco.cc/trials/nct07123454/), [A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies](https://onco.cc/trials/nct05643742/), [A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL](https://onco.cc/trials/nct04496349/), [A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies](https://onco.cc/trials/nct05207670/), [A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies](https://onco.cc/trials/nct06564038/), [A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma](https://onco.cc/trials/nct02979522/), [A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma](https://onco.cc/trials/nct06915246/), [A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer](https://onco.cc/trials/nct06521567/), [A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)](https://onco.cc/trials/nct02332668/), [A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas](https://onco.cc/trials/nct06090539/), [A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly](https://onco.cc/trials/nct05950165/), [A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat](https://onco.cc/trials/nct03888105/), [A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th](https://onco.cc/trials/nct05201248/), [A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl](https://onco.cc/trials/nct05283720/), [A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu](https://onco.cc/trials/nct05533775/), [A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma](https://onco.cc/trials/nct03671018/), [A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy](https://onco.cc/trials/nct07188558/), [A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl](https://onco.cc/trials/nct04002297/), [A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ](https://onco.cc/trials/nct06230224/), [AETHERA](https://onco.cc/trials/aethera/), [AHOD1331](https://onco.cc/trials/ahod1331/), [AHOD2131 (COG / NCTN)](https://onco.cc/trials/ahod2131/), [An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma](https://onco.cc/trials/nct03533283/), [AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.](https://onco.cc/trials/nct06137144/), [BMT CTN 0803](https://onco.cc/trials/bmt-ctn-0803/), [CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma](https://onco.cc/trials/nct06479356/), [CheckMate 205](https://onco.cc/trials/checkmate-205/), [Childhood Cancer Survivor Study (CCSS)](https://onco.cc/trials/ccss/), [Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma](https://onco.cc/trials/nct07730515/), [ECHELON-1](https://onco.cc/trials/echelon-1/), [EuroNet-PHL-C2](https://onco.cc/trials/euronet-phl-c2/), [Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL](https://onco.cc/trials/nct06806033/), [GHSG HD21](https://onco.cc/trials/hd21/), [IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers](https://onco.cc/trials/nct06119685/), [KEYNOTE-204](https://onco.cc/trials/keynote-204/), [MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)](https://onco.cc/trials/nct06534437/), [NHS-Galleri](https://onco.cc/trials/nhs-galleri/), [Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)](https://onco.cc/trials/nct04268706/), [Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma](https://onco.cc/trials/nct00742027/), [RATHL](https://onco.cc/trials/rathl/), [Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma](https://onco.cc/trials/nct01037478/), [Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL](https://onco.cc/trials/nct04502394/), [Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)](https://onco.cc/trials/nct03407144/), [Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma](https://onco.cc/trials/nct05338931/), [Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma](https://onco.cc/trials/nct05607420/), [Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma](https://onco.cc/trials/nct02180711/), [Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma](https://onco.cc/trials/nct05826535/), [Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies](https://onco.cc/trials/nct04068597/), [Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL](https://onco.cc/trials/nct06526793/), [SWOG S1826](https://onco.cc/trials/swog-s1826/), [T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)](https://onco.cc/trials/nct06343311/), [Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader](https://onco.cc/trials/nct05294731/)
- journals: [Clinical lymphoma, myeloma & leukemia](https://onco.cc/journals/clinical-lymphoma-myeloma-and-leukemia/), [Current hematologic malignancy reports](https://onco.cc/journals/current-hematologic-malignancy-reports/), [Hematological oncology](https://onco.cc/journals/hematological-oncology/), [Journal of adolescent and young adult oncology](https://onco.cc/journals/journal-of-adolescent-and-young-adult-oncology/), [Leukemia & lymphoma](https://onco.cc/journals/leukemia-and-lymphoma/)
- ideas: [A live stock-out map for essential chemotherapy drugs](https://onco.cc/ideas/idea-acc-chemo-stockout-early-warning/), [A survivorship passport app for adolescent and young adult survivors](https://onco.cc/ideas/idea-acc-aya-survivorship-passport/), [A survivorship research endowment funded by a levy on curative therapy prices](https://onco.cc/ideas/idea-fund-survivorship-endowment-levy/), [An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas](https://onco.cc/ideas/idea-prev-ebv-vaccine/), [Cash for transport and food to stop families abandoning curative treatment](https://onco.cc/ideas/idea-acc-abandonment-stipends/), [CD30 CAR-T for multiply relapsed Hodgkin lymphoma](https://onco.cc/ideas/idea-cd30-car-t-hodgkin/), [Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage](https://onco.cc/ideas/idea-chemo-free-hodgkin/), [Default fertility preservation referral for every patient under 40 before treatment](https://onco.cc/ideas/idea-acc-default-fertility-preservation-referral/), [Fertility preservation offered and funded by default before gonadotoxic treatment](https://onco.cc/ideas/idea-moon-fertility-preservation-default/), [Guaranteed-quality childhood cancer medicines free of charge in 50 countries](https://onco.cc/ideas/idea-acc-childhood-medicines-platform-scale/), [Let adolescents from age 12 into adult trials when the cancer biology is the same](https://onco.cc/ideas/idea-tr1-age-floor-twelve-for-adult-trials/), [Nurse-led chemotherapy day units with a doctor on a screen](https://onco.cc/ideas/idea-acc-nurse-led-chemotherapy-units/), [Stop over-excluding people who could become pregnant; study pregnancy exposure](https://onco.cc/ideas/idea-tr1-include-pregnancy-capable-people-sensibly/), [Tailored screening for second cancers in survivors with known high-risk exposures](https://onco.cc/ideas/idea-acc-tailored-second-cancer-screening/)
- cancers: [Adolescent and young adult cancers (ages 15 to 39)](https://onco.cc/cancers/aya-cancers/), [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Early-stage classical Hodgkin lymphoma (stage I to II)](https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/), [HIV-associated (AIDS-related) lymphomas](https://onco.cc/cancers/hiv-associated-lymphoma/), [Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)](https://onco.cc/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Post-transplant lymphoproliferative disorder (PTLD)](https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/), [Primary mediastinal (thymic) large B-cell lymphoma](https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/)
- people: [Alex F. Herrera](https://onco.cc/people/alex-herrera/), [Andreas Engert](https://onco.cc/people/andreas-engert/), [Armando Santoro](https://onco.cc/people/armando-santoro/), [Emil "Tom" Frei III](https://onco.cc/people/emil-frei/), [Joseph M. Connors](https://onco.cc/people/joseph-connors/), [Kara M. Kelly](https://onco.cc/people/kara-kelly/), [Peter Borchmann](https://onco.cc/people/peter-borchmann/), [Peter Johnson](https://onco.cc/people/peter-johnson/), [Sirpa Leppä](https://onco.cc/people/sirpa-leppa/), [Vinod Raina](https://onco.cc/people/raina-vinod/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)
- collections: [Leukemia & Lymphoma Society (LLS)](https://onco.cc/collections/leukemia-lymphoma-society/), [Lymphoma Research Foundation (LRF)](https://onco.cc/collections/lymphoma-research-foundation/)
- key papers: [AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma](https://onco.cc/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/), [ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma](https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/), [Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial](https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/), [SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults](https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/)
- pathways: [Oncogenic viruses](https://onco.cc/pathways/oncogenic-viruses/)
- biomarkers: [CD30 expression (CD30-positive)](https://onco.cc/biomarkers/cd30-expression/)

---
JSON: https://onco.cc/api/v1/entities/hodgkin-lymphoma.json